In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins

We compared the in vitro antibacterial activity of DU-6681a against Gram-po sitive and Gramnegative bacteria with that of R-95867, faropenem and oral c ephalosporins such as cefcapene, cefotiam and cefpodoxime, DU-6681a is an a ctive form of the new oral carbapenem compound DZ-2640, which is an ester-t ype prodrug, and R-95867 is an active form of the oral carbapenem CS-834. A gainst most Gram-positive bacteria, DU-6681 a was as active as or two- to 1 6-fold more potent than R-95867 and faropenem in terms of MIC90, and compar able to or two- to 64-fold move effective than the cephalosporins. Against most Gram-negative bacteria, the activity of DU-6681a was the same as or tw o- to 16-fold more patent than that of R-95867, and comparable to or two- t o 2048-fold higher than that of faropenem and the cephalosporins.